Hostname: page-component-5c6d5d7d68-thh2z Total loading time: 0 Render date: 2024-08-06T22:25:21.995Z Has data issue: false hasContentIssue false
  • English
  • Français

The New Prospective Payment System and Antibiotic Utilization

Published online by Cambridge University Press:  02 January 2015

Peter A. Gross
Peter A. Gross*
Affiliation:
Hackensack Medical Center Hackensack, New Jersey
*
Department of Internal Medicine, Hackensack Medical Center, 30 Prospect Avenue, Hackensack, NJ 07601
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Infection Control & Hospital Epidemiology , Volume 5 , Issue 7 , July 1984 , pp. 319 - 320
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1984

References

1.Iglehart, JK, The new era of prospective payment for hospitals. N Engl J Med 1982;307:1288–1292.CrossRefGoogle ScholarPubMed
2.Iglehart, JK, New Jersey's experiment with DRG-based hospital reimbursement. N Engl J Med 1982;307:1655–1660.CrossRefGoogle ScholarPubMed
3.Shakno, R (ed): Physicians Guide to DRGs. Chicago, Pluribus Press, 1984, pp 232.Google Scholar
4.Ginzberg, E, Cost containment—Imaginary and real. N Engl J Med 1983;308:1220–1224.CrossRefGoogle ScholarPubMed
5.Piatt, R, Cost containment—Another view. N Engl J Med 1983;309:726–730.Google Scholar
6.Kunin, CM, Evaluation of antibiotic usage: A comprehensive look at alternative approaches. Rev Infect Dis 1981;3:745–753.CrossRefGoogle Scholar
7.Curtis, FR, Pharmacy management strategies for responding to hospital reimbursement changes. Am J Hosp Pharm 1983;40:1489–1492.Google Scholar
8.Smith, CR, Lipsky, JJ, Laskin, OL, et al: Double-blind comparison of. the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980;302:1106–1109.CrossRefGoogle ScholarPubMed
9.Durgin, WA, Lapidas, B, Goldmann, DA, Improved antibiotic usage following introduction of a novel prescription system. JAMA 1981;146:1796–1800.Google Scholar
10.Antimicrobial prophylaxis for surgery. The Medical Letter 1983;25(issue 651): 113–116.Google Scholar
11.Barriere, SL, Hatheway, GJ, Gambertoglio, JG, et al: Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin. Antimicrob Agents Phemother 1982;21:935–938.CrossRefGoogle ScholarPubMed
12.Kirby, WMM, Regamey, C, Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis 1973;128:S341–346.CrossRefGoogle ScholarPubMed
13.Neu, HC, The new beta-lactamase-stable cephalosporins. Ann Intern Med 1982;97:408–419.CrossRefGoogle ScholarPubMed
14.Nelson, JD, A primer for pediatricians on new cephalosporin antibiotics. Am J Dis Child 1983;137:1041–1042.Google ScholarPubMed
15.Poretz, DM, Eron, LJ, Goldenberg, RI, et al: Intravenous antibiotic therapy in an outpatient setting. JAMA 1982;248:336–339.CrossRefGoogle Scholar
16.Souney, P, Polk, BF, Single-dose antimicrobial therapy for urinary tract infections in women. Rev Infect Dis 1982;4:29–34.CrossRefGoogle ScholarPubMed
17.Ticarcillin. The Medical Letter 1977;19(4:17–18.Google Scholar